The Impact of QT ‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Hsiu-Ting Chien und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Long QT Syndrome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Researchers have studied potential corrected QT interval (QTc) prolongation from drug–drug interactions (DDIs), raising unresolved questions about their real‐world impact. This retrospective case‐crossover study investigated the effects of QT‐prolonging drugs and DDIs on QTc prolongation in hospitalized patients aged 45 years and above. The cohort comprised patients who had multiple hospitalizations and developed QTc prolongation (QTc > 500 ms or an increase of >60 ms from baseline) at least 24 hours after admission between 2011 and 2019. Conditional logistic regression compared drug exposure between hospitalizations with QTc prolongation (case window) and those without (reference window). Among 2,276 patients (mean age 71; 43.8% female), the use of QT‐prolonging drugs significantly increased the risk of QTc prolongation (odds ratio: 2.42 (95% confidence interval: 1.95–3.02)). The risk was higher with drugs of “known risks” (OR: 3.78 (2.91–4.90)) and “conditional risk” (OR: 2.08 (1.65–2.62)). DDIs, particularly involving multiple “known risk” drugs (OR: 7.86 (4.96–12.45)), strong cytochrome P450 enzyme inhibitors (OR: 5.57 (2.75–11.30)), or the concurrent use of ≥4 QT‐prolonging drugs with any risk (OR: 5.28 (3.96–7.03)) substantially increased the risk. Cautious prescribing for patients with multiple risk factors is important to minimize the likelihood of QTc prolongation. However, when considering enhanced monitoring or drug choices, it is crucial to carefully evaluate the overall risk of QT prolongation against the benefits of treatment to ensure optimal patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Heart Failure Center, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pharmacy, National Taiwan University Cancer Center, Taipei, Taiwan.
ORCID-Profile: Hsiu-Ting Chien, Fang-Ju Lin, Jyh-Ming Jimmy Juang, Shu-Wen Lin
Zitieren
APA
Chien, H. T., Lin, F. J., Juang, J. J., & Lin, S. W. (2025). The Impact of QT ‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3469
Vancouver
Chien HT, Lin FJ, Juang JJ, Lin SW. The Impact of QT ‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3469
BibTeX
@article{Chien2025,
author = {Chien, Hsiu-Ting and Lin, Fang-Ju and Juang, Jyh-Ming Jimmy and Lin, Shu-Wen},
title = {The Impact of QT ‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3469}
}
EUVIMED